Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 5mg | $44.99 | $9.00/mg | In stock | Jul 4 |
| vial | 15mg | $111.99 | $7.47/mg | In stock | Jul 4 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| KC-CJN-WHT2 | Mar 2026 | 99.9% | Freedom Diagnostics | — | Unverified | View |
| KC-CJD-BLU1 | Oct 2025 | 99.6% | Freedom Diagnostics | — |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. CJC-1295 is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Kimera Chems sell CJC-1295?
Yes — Kimera Chems currently lists CJC-1295 in 2 variants starting at $111.99 ($7.47/mg).
Is Kimera Chems's CJC-1295 third-party tested?
Yes — Disclosed Labs has indexed 7 Certificates of Analysis for Kimera Chems's CJC-1295, with the most recent showing 99.9% purity. Kimera Chems holds an overall trust grade of C (70/100) across all 355 COAs on file.
What is Kimera Chems's trust grade for CJC-1295?
Kimera Chems has an overall Disclosed Labs trust grade of C (70/100), computed from 355 COAs across all peptides. The most recent CJC-1295 COA was issued by Freedom Diagnostics.
Where is the cheapest CJC-1295?
As of the latest data, Peptide Supply Co. offers CJC-1295 at $3.80/mg — compare with Kimera Chems's listing at $7.47/mg. See the full CJC-1295 price comparison.
Is CJC-1295 legal to buy?
CJC-1295 is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| Confirmed |
| View |
| Yellow Cap | Nov 2024 | 99.1% | Vanguard Laboratory | — | Unverified | View |
| Black Cap | — | 99.8% | Vanguard Laboratory | — | Unverified | View |
| KC-CJN-BLK1 | — | 99.8% | Vanguard Laboratory | Endotoxin, Sterility, Heavy metals | Confirmed | View |
| KC-CJN-ORG1 | — | 99.9% | TrustPointe Analytics | — | Confirmed | View |
| KC-CJN-WHT1 | — | 95.1% | TrustPointe Analytics | — | Unverified | View |
Disclosed Labs